Artiam Bio is developing refined type 1 cannabinoid receptor antagonists to treat non-alcoholic steatohepatitis (NASH), cannabis use disorder (CUD), and Prader-Willi Syndrome (PWS) by minimizing the risks associated with earlier CB1 antagonists. Their patented portfolio includes over 400 small molecules aimed at providing safe and effective treatment options for over 30 million patients in the U.S.
Funding
$70.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Non-alcoholic steatohepatitis (NASH), cannabis use disorder (CUD), and Prader-Willi Syndrome (PWS) are severe diseases affecting millions, yet safe and effective treatment options remain limited. Existing therapies may have adverse effects, highlighting the need for more targeted and well-tolerated interventions.
Solution
Artiam Bio is developing a portfolio of refined type 1 cannabinoid receptor (CB1) antagonists designed to treat NASH, CUD, and PWS. Their approach focuses on minimizing the risks associated with earlier CB1 antagonists, aiming to deliver life-altering outcomes without mind-altering adverse effects. By leveraging their expertise in cannabinoid receptor biology, Artiam Bio seeks to create novel, small molecule drugs that address the unmet needs of patients suffering from these conditions. The company's strategy is based on pre-clinical and clinical evidence suggesting that CB1 blockade is a promising therapeutic avenue.
Target Audience
The primary target audience includes individuals suffering from non-alcoholic steatohepatitis (NASH), cannabis use disorder (CUD), and Prader-Willi Syndrome (PWS).
Features
- Patented portfolio of over 400 small molecule CB1 antagonists
- Focus on minimizing adverse effects associated with earlier CB1 antagonists
- Targeting clinically proven CB1 receptor with a de-risked strategy
- Development of novel, small molecule drugs
- Addressing NASH, CUD, and PWS indications